Genting TauRx Diagnostic Centre Sdn. Bhd. (“GTD”) is committed to creating a service and technology platform which focuses on early diagnosis of patients suffering from a range of cognitive disorders, including Alzheimer’s Disease (“AD”) and Fronto-Temporal Dementia (“FTD”). GTD is developing innovative tools and systems required to permit early detection and support the diagnosis of AD, FTD and other related disorders. Headquartered in Kuala Lumpur, the major shareholders of GTD are Genting Berhad and TauRx Pharmaceuticals Ltd.